Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R.W. Johnson Mylinax

Executive Summary

FDA cancels Jan. 29 meeting of the Peripheral & Central Nervous System Drugs Advisory Committee. The committee was scheduled to review Mylinax (cladribine) for treatment of multiple sclerosis
Advertisement

Related Content

Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004
Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004
Advertisement
UsernamePublicRestriction

Register

PS033494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel